Abstract

A pathophysiological taxonomy: A pathophysiological classification of membrane dysfunction, which provides mechanistic links to functional characteristics, should be used when prescribing individualized dialysis or when planning modality transfer (e.g. to automated peritoneal dialysis (PD) or haemodialysis) in the context of shared and informed decision-making with the person on PD, taking individual circumstances and treatment goals into account. (practice point). Identification of fast peritoneal solute transfer rate (PSTR): It is recommended that the PSTR is determined from a 4-h peritoneal equilibration test (PET), using either 2.5%/2.27% or 4.25%/3.86% dextrose/glucose concentration and creatinine as the index solute. (practice point) This should be done early in the course dialysis treatment (between 6 weeks and 12 weeks) (GRADE 1A) and subsequently when clinically indicated. (practice point). Clinical implications and mitigation of fast solute transfer: A faster PSTR is associated with lower survival on PD. (GRADE 1A) This risk is in part due to the lower ultrafiltration (UF) and increased net fluid reabsorption that occurs when the PSTR is above the average value. The resulting lower net UF can be avoided by shortening glucose-based exchanges, using a polyglucose solution (icodextrin), and/or prescribing higher glucose concentrations. (GRADE 1A) Compared to glucose, use of icodextrin can translate into improved fluid status and fewer episodes of fluid overload. (GRADE 1A) Use of automated PD and icodextrin may mitigate the mortality risk associated with fast PSTR. (practice point). Recognizing low UF capacity: This is easy to measure and a valuable screening test. Insufficient UF should be suspected when either (a) the net UF from a 4-h PET is <400 ml (3.86% glucose/4.25% dextrose) or <100 ml (2.27% glucose /2.5% dextrose), (GRADE 1B) and/or (b) the daily UF is insufficient to maintain adequate fluid status. (practice point) Besides membrane dysfunction, low UF capacity can also result from mechanical problems, leaks or increased fluid absorption across the peritoneal membrane not explained by fast PSTR. Diagnosing intrinsic membrane dysfunction (manifesting as low osmotic conductance to glucose) as a cause of UF insufficiency: When insufficient UF is suspected, the 4-h PET should be supplemented by measurement of the sodium dip at 1 h using a 3.86% glucose/4.25% dextrose exchange for diagnostic purposes. A sodium dip ≤5 mmol/L and/or a sodium sieving ratio ≤0.03 at 1 h indicates UF insufficiency. (GRADE 2B). Clinical implications of intrinsic membrane dysfunction (de novo or acquired): in the absence of residual kidney function, this is likely to necessitate the use of hypertonic glucose exchanges and possible transfer to haemodialysis. Acquired membrane injury, especially in the context of prolonged time on treatment, should prompt discussions about the risk of encapsulating peritoneal sclerosis. (practice point). Additional membrane function tests: measures of peritoneal protein loss, intraperitoneal pressure and more complex tests that estimate osmotic conductance and 'lymphatic' reabsorption are not recommended for routine clinical practice but remain valuable research methods. (practice point). Socioeconomic considerations: When resource constraints prevent the use of routine tests, consideration of membrane function should still be part of the clinical management and may be inferred from the daily UF in response to the prescription. (practice point).

Highlights

  • IntroductionThe International Society of Peritoneal Dialysis has not produced a guideline on the assessment of peritoneal membrane function since 2000.1 The most recent comprehensive guideline on this important issue was from the European Best Practice guideline group in 2010.2 This is despite the fact that over the last two decades there has been mounting evidence that peritoneal membrane function is an Peritoneal Dialysis International 41(4)

  • What is the purpose of this guideline?The International Society of Peritoneal Dialysis has not produced a guideline on the assessment of peritoneal membrane function since 2000.1 The most recent comprehensive guideline on this important issue was from the European Best Practice guideline group in 2010.2 This is despite the fact that over the last two decades there has been mounting evidence that peritoneal membrane function is an Peritoneal Dialysis International 41(4)important predictor of clinical outcomes, especially survival, and the considerable increase in our understanding of the changes in membrane function that occur over time on dialysis and the underlying mechanisms of peritoneal membrane injury

  • We have provided a brief description of how the membrane can be described by theoretical and animal models followed by an updated classification of membrane dysfunction that uses the insights from these models to integrate function with underlying membrane physiology and pathophysiology

Read more

Summary

Introduction

The International Society of Peritoneal Dialysis has not produced a guideline on the assessment of peritoneal membrane function since 2000.1 The most recent comprehensive guideline on this important issue was from the European Best Practice guideline group in 2010.2 This is despite the fact that over the last two decades there has been mounting evidence that peritoneal membrane function is an Peritoneal Dialysis International 41(4). Over time there has been a paradigm shift away from defining the efficacy of dialysis treatment in terms of small solute clearance,[3,4,5] with the realization that at least equal weight should be placed on fluid management and outcomes important to people on dialysis.[6,7] Recent epidemiological studies have consistently shown a strong and independent association between fluid overload and poor outcome, including mortality, among patients with kidney failure on dialysis.[8,9] Volume overload is highly prevalent among patients on peritoneal dialysis (PD), with more than 50% of individuals showing some degree of hypervolemia and 25% being severely volume overloaded.[10,11] high-quality PD prescription should aim to achieve and maintain fluid and salt homeostasis, through preservation of residual kidney function including urine volume and natriuresis, dietary counselling and peritoneal ultrafiltration (UF), the latter being the focus of this guideline and especially important when there is little or no residual kidney function.[6,12,13,14] High-quality dialysis prescription is defined in terms of an individualized goal-directed approach.[7] This necessitates the measurement of individual membrane function and appreciation of the implications this has for shared clinical decision-making It is clear from the SONG-PD initiative that patients, carers and their clinicians rate the importance membrane function highly along with its implications for technique failure, survival and cardiovascular outcomes.[15,16]. Clinical case examples to illustrate the different types of membrane problem, including cases in which poor net fluid removal was not due to membrane dysfunction (e.g. catheter dysfunction, leaks), are given in the Online Supplement Appendices along with a glossary of technical definitions used and a detailed description of how membrane function tests should be performed

Methods
Discussion
Findings
Ethical approval Not applicable
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call